March 26, 2012

Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody

– New Data Presented at American College of Cardiology Meeting Demonstrate Reductions of 40% to 72% in LDL-Cholesterol in Patients on Statins –

 

Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody
– New Data Presented at American College of Cardiology Meeting Demonstrate Reductions of 40% to 72% in LDL-Cholesterol in Patients on Statins –

Paris, France and Tarrytown, NY – March 26, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.